Delving into the Latest Updates on Tasly International Gene Network Drug Innovation Center Co., Ltd. with Synapse

Overview

Tags

Congenital Disorders

Nervous System Diseases

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

GABAB receptor x Opioid receptors x mAChRs	1

Main study objectives: To observe the metabolism of (RS)-baclofen and naltrexone hydrochloride in healthy Chinese subjects after single and multiple oral administration of PXT3003, and to calculate the corresponding pharmacokinetic parameters. Secondary study objectives: To observe the safety of PXT3003 in healthy Chinese subjects.

Start Date24 Oct 2022

Sponsor / Collaborator

Tasly International Gene Network Drug Innovation Center Co., Ltd.

NCT05092841 / Unknown statusPhase 3

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) Treated 15 Months

This is a randomized, double-blind, placebo-controlled and multicenter 3 phase trial evaluating the therapeutic effect and safety of CMT1A by PXT3003. This double-blind study will assess in parallel groups 1 dose of PXT3003 compared to Placebo in CMT1A patients treated for 15 months.

Start Date28 Sep 2021

Sponsor / Collaborator

Tasly International Gene Network Drug Innovation Center Co., Ltd.

CTR20211722 / CompletedPhase 3

评估PXT3003治疗1A型腓骨肌萎缩症15个月的疗效和安全性的多中心、随机、双盲、安慰剂对照III期临床试验

[Translation] A multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of PXT3003 in the treatment of Charcot-Marie-Tooth Disease Type 1A for 15 months

主要研究目的：通过总体神经功能限制量表（ONLS）评估PXT3003治疗1A型腓骨肌萎缩症（CMT1A）15个月的有效性。次要研究目的：通过功能学检测、电生理参数和生活质量参数评估PXT3003的有效性；评估PXT3003的安全性。

[Translation]

Primary study objectives: To evaluate the 15-month efficacy of PXT3003 in the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A) using the Overall Neurological Limitation Scale (ONLS). Secondary study objectives: To evaluate the efficacy of PXT3003 using functional tests, electrophysiological parameters, and quality of life parameters; to evaluate the safety of PXT3003.

Start Date26 Sep 2021

Sponsor / Collaborator

Tasly International Gene Network Drug Innovation Center Co., Ltd.

100 Clinical Results associated with Tasly International Gene Network Drug Innovation Center Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Tasly International Gene Network Drug Innovation Center Co., Ltd.

Login to view more data

100 Deals associated with Tasly International Gene Network Drug Innovation Center Co., Ltd.

Login to view more data

100 Translational Medicine associated with Tasly International Gene Network Drug Innovation Center Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data